---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-090878"
form_type: "8-K"
ticker: "ACXP"
cik: "0001736243"
company_name: "Acurx Pharmaceuticals, Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T11:53:00.211564+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Acurx Pharma Q2 net loss widens to $3.4M; Phase 2b enrollment ongoing

## Summary
- Net loss Q2 2023: $3.4M ($0.28/sh) vs $2.6M ($0.26/sh) in Q2 2022.
- Cash unchanged at $9.1M as of June 30, 2023; no revenue reported.
- Phase 2b trial for ibezapolstat in C. difficile: 28 sites enrolling; 5 patients needed for interim IDMC review.
- R&D expenses rose to $1.7M (Q2 2023) from $0.9M (Q2 2022) driven by Phase 2b costs.
- CARB-X declined grant for ACX375C pre-clinical candidate; encouraged re-application.

## SEC filing metadata
- accession: 0001104659-23-090878
- form_type: 8-K
- ticker: ACXP
- cik: 0001736243
- company_name: Acurx Pharmaceuticals, Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736243/000110465923090878/0001104659-23-090878-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736243/000110465923090878/tm2323535d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-090878
- JSON: https://secwatch.observer/filing/0001104659-23-090878.json
- Plain text: https://secwatch.observer/filing/0001104659-23-090878.txt

## Key facts
- Earnings Releases
  Acurx Pharmaceuticals, Inc. reported the second quarter ended June 30, 2023 results: net income a net loss of $3.4 million or $0.28 per diluted share, EPS $0.28 per diluted share.
  - Period: the second quarter ended June 30, 2023
  - Net income: a net loss of $3.4 million or $0.28 per diluted share
  - EPS: $0.28 per diluted share
  - Result: reported results
  source text: The Company reported a net loss of $3.4 million or $0.28 per diluted share for the three months ended June 30, 2023, compared to a net loss of $2.6 million or $0.26 per diluted share for the three months ended June 30, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1736243/000110465923090878/0001104659-23-090878-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.